secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0001193125-24-250984
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm Q3 total revenue $38.8M, net loss $32.1M; narrows FY2024 guidance
----------------------------------------------------------------------------

- U.S. XPOVIO net product revenue $29.5M in Q3, down from $30.2M in Q3 2023; total revenue up to $38.8M from $36.0M.
- Net loss $32.1M ($0.26/share) vs $34.5M ($0.30/share) in Q3 2023; R&D expenses increased to $36.1M.
- FY2024 total revenue guidance narrowed to $145-155M; XPOVIO revenue guidance narrowed to $110-115M.
- Phase 3 SENTRY myelofibrosis trial endpoint changed to Abs-TSS; sample size increased to ~350; top-line data expected 2H 2025.
- Cash and investments $133.9M; cash runway into Q1 2026 (excluding $24.5M convertible note due Oct 2025).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312524250984/0001193125-24-250984-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312524250984/d906207d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-250984

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer